Clinical Updates in Psoriatic Arthritis


The Rheumatology Network psoriatic arthritis clinical focus page provides information on the latest psoriatic arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for psoriatic arthritis drugs.

Philip J Mease, MD: Efficacy of Guselkumab for Reducing Fatigue in Psoriatic Arthritis

August 04, 2021

Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”

Q&A: Ustekinumab Versus TNF Inhibition in Psoriatic Arthritis

August 03, 2021

In this Q&A, corresponding author Josef S Smolen, MD, discussed the findings of his study determining the effectiveness of ustekinumab versus tumor necrosis factor inhibition in patients with psoriatic arthritis.

Tofacitinib and Adalimumab Significantly Improved Pain for Patients With Psoriatic Arthritis

July 13, 2021

“This analysis provides information on when clinically meaningful improvements in pain may be expected in patients with psoriatic arthritis receiving tofacitinib or adalimumab, and how baseline pain severity may impact response to tofacitinib, which is of value in clinical practice,” stated investigators.